CBIO Q3 2021 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86,560-91.3% YoY

Gross Profit

$86,560100.0% margin

Operating Income

-$17M-20028.8% margin

Net Income

-$17M-20023.5% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+60857.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$108M

Total Liabilities

$11M

Stockholders' Equity

$97M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86,560	$1M	-91.3%
Gross Profit	$86,560	$1M	-91.3%
Operating Income	-$17M	-$14M	-26.3%
Net Income	-$17M	-$14M	-26.3%